Alzheimer’s disease is the most common form of dementia, affecting millions of people worldwide. This disease affects the parts of the brain that control memory, thinking, and language. Most commonly, people with Alzheimer’s disease begin to show symptoms. mid 60’s. Scientists have shown that some rare cases of Alzheimer’s disease are caused by a genetic mutation known as PSEN1-E280A, which causes people to develop Alzheimer’s disease as early as their mid-40s, and that this The condition is called early-onset Alzheimer’s disease.
Scientists have identified a Colombian man who carries the gene for early-onset Alzheimer’s disease and a second genetic mutation called the RELN-COLBOS mutation. This man maintained a fully functioning brain for about 30 years longer than the average person with early-onset Alzheimer’s disease. Scientists hypothesized that his genetic mutation could help develop treatments to help others resist Alzheimer’s disease. But additional case studies were needed to find out whether the genetic mutation was the sole reason for the man’s resistance to the disease.
Researchers in Columbia recently set out to study patients with the RELN-COLBOS mutation to see how it may help fight early-onset Alzheimer’s disease. They enrolled the patient in an international collaboration.Antioch University in Columbia and Massachusetts General Hospital in Boston; called Columbia-Boston Biomarker Research Program.This program includes: More than 6,000 participants took part, including those with and without genes known to cause Alzheimer’s disease.
Researchers compared a Colombian man with the RELN-COLBOS mutation to young-onset Alzheimer’s disease patients who do not carry this mutation to determine whether they develop the disease through different pathways. They compared each patient’s cognitive decline in terms of their motor function, number of neurons firing in their brains, and signal strength. They also measured proteins in each patient’s brain that are known to help with memory and learning, such as Dab1 and Tau proteins.
The researchers also collected brain tissue from the man. They performed a type of genetic profiling called. Single cell RNA sequencing Examining his brain tissue revealed that he PSEN1-E280A Gene that causes early-onset Alzheimer’s disease. They used this same method to determine which RELN mutation he had.
They explained that the RELN gene normally tells the body how to make the protein Reelin, which controls brain development.. This man had a mutation in his RELN gene that codes for a different amino acid. Researchers have observed similar mutations in people with other brain-related diseases such as schizophrenia, bipolar disorder, and autism. They named it the RELN-COLBOS mutation, after their research program.
The researchers then looked at the men’s brains using several medical imaging techniques, including positron emission tomography. PET scanmagnetic resonance imaging, or MRI scan. They examined these images of the man’s brain for signs of disease or other abnormalities.
They found that the men’s brains contained large amounts of amyloid beta protein. They explained that this protein causes the loss of neurons and neural connections in Alzheimer’s patients.But the men’s brains were also found to have lower-than-normal levels of another protein called tau protein, which is usually associated with Alzheimer’s disease.. They explained that Alzheimer’s patients typically have high amounts of the protein tau, which disrupts the internal skeleton of neurons and impairs thinking and memory. The researchers suggested that the man’s low levels of tau protein in his brain were part of his resistance to Alzheimer’s disease.
Based on how the RELN-COLBOS mutation acted in this man, scientists hypothesized that it was the cause. Gain-of-function (GOF) mutations. GOF mutations occur when a mutated gene acquires a new function. In other words, it will work differently than it should. For example, a coffee machine’s function is to make coffee, but a GOF mutation could cause it to start making orange juice instead. They classified the RELN-COLBOS mutation as a GOF mutation because the normal function of the RELN gene is to produce the Reelin protein, but the mutant form instead slows down the production of the tau protein.
The researchers concluded that the new function of the RELN-COLBOS mutation may help the gene regulate neural circuits damaged by Alzheimer’s disease and other types of dementia. However, the researchers cautioned that the mutation’s impact on these diseases is modest, as it slows but does not prevent cognitive impairment. They say there are currently only a handful of cases available and that different genetic mutations may delay Alzheimer’s symptoms in the same patient, so future researchers could study other patients with the same mutations. I suggested that it should be done.
Post views: 767
Source: sciworthy.com
